Integra LifeSciences (IART) Wells Fargo 21st Annual Healthcare Conference summary

Key performance indicators and execution

• Revenue met or exceeded expectations in the first two quarters, driven by improved supply reliability and operational discipline.

• Focus remains on consistent execution, margin expansion, cash flow improvement, and deleveraging.

• Commercial execution and product relaunches are expected to drive long-term growth.

• Innovation strategy includes progress on PMAs and expanded indications, especially in implant-based breast reconstruction.

Growth opportunities and market outlook

• Specialty surgery saw low single-digit growth in Q2, with international markets expected to gain momentum into 2027.

• International business is projected to return to mid- to high-single-digit growth by 2027.

• Improved supply predictability is shifting commercial focus to clinical conversations, boosting sales force confidence.

• Strong competitive advantages include deep customer relationships and clinically proven product lines.

Financial guidance and cost initiatives

• Organic growth guidance for 2026 is 0.8%-3.3%, with execution consistency as the main driver.

• EBITDA margin is expected to improve by 100 basis points in 2026, mainly from gross margin gains and OpEx efficiencies.

• Remediation plan milestones include the Q4 relaunch of SurgiMend and operationalization of the Braintree site.

• Cost-saving initiatives are set to deliver $25M-$30M in 2026 and an incremental $10M-$15M in 2027.